Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication

International Immunology

Volumn 24, Issue 2, 2012, Pages 117-128

  Jun, SangMu ^a   Clapp, Beata ^a   Zlotkowska, Dagmara ^b   Hoyt, Teri ^a   Holderness, Kathryn ^a   Maddaloni, Massimo ^a   Pascual, David W ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

Author keywords

Adjuvant; Mucosal vaccine targeting; Neutralizing antibody

Indexed keywords

ADENOVIRUS VECTOR; BOTULINUM TOXIN A; CHOLERA TOXIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; OVALBUMIN ADENOVIRUS 2 FIBER PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOTULISM; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG UPTAKE; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VACCINATION;

EID: 84856623825     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr106     Document Type: Article

References (66)

1. McGhee, J. R. and Kiyono, H. 2003. The mucosal immune system. Chapter 31. In Paul, W. E., ed., Fundamental Immunology, 5th ed., p. 965. Lippincott Williams & Willkins, Philadelphia, PA.
2. Holmgren, J. and Czerkinsky, C. 2005. Mucosal immunity and vaccines. Nat. Med. 11 (4 Suppl):S45.
3. Li, Z., Zhang, M., Zhou, C., Zhao, X., Iijima, N. and Frankel, J. R. 2008. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J. Immunol. 180:2504.
4. + T cell responses. J. Immunol. 166:1106.
5. Ranasinghe, C., Turner, S. J., McArthur, C. et al. 2007. Mucosal HIV-1 Pox Virus Prime-boost Immunization Induces High-avidity CD8+ T Cells with Regime-dependent Cytokine/granzyme B Profiles [published erratum appears in J. Immunol. 178:8221]. J. Immunol. 178:2370.
6. Czerkinsky, C. and Holmgren, J. 2012. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol. 354, in press.
7. Kunkel, E. J. and Butcher, E. C. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822.
8. Csencsits, K. L., Walters, N. and Pascual, D. W. 2001. Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: alpha(E) versus L-selectin. J. Immunol. 167:2441.
9. Quiding-Jisärbrink, M., Nordström, I., Granström, G. et al. 1997. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99:1281.
10. Bienenstock, J. and McDermott, M. R. 2005. Bronchus- and nasalassociated lymphoid tissues. Immunol. Rev. 206:22.
11. Johansson, E. L., Wassén, L., Holmgren, J., Jertborn, M. and Rudin, A. 2001. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69:7481.
12. Bergquist, C., Johansson, E. L., Lagergård, T., Holmgren, J. and Rudin, A. 1997. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65:2676.
13. Armstrong, M. E., Lavelle, E. C., Loscher, C. E., Lynch, M. A. and Mills, K. H. 2005. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J. Infect. Dis. 192: 1628.
14. Lemiale, F., Kong, W. P., Akyürek, L. M. et al. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078.
15. van Ginkel, F. W., Jackson, R. J., Yuki, Y. and McGhee, J. R. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165:4778.
16. Couch, R. B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350:860.
17. Mutsch, M., Zhou, W., Rhodes, P. et al. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896.
18. WHO. 2002. Statement from the Global Advisory Committee on Vaccine Safety. Bell's Palsy Following Vaccination with Intranasal Vaccine. World Health Organization, Geneva, Switzerland. Available at: http://www.who.int/vaccines-surveillance/ISPP/hotbellsPalsy. shtml.
19. Lewis, D. J., Huo, Z., Barnett, S. et al. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999.
20. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
21. Zhang, H., Zhang, J. and Streisand, B. 2002. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 41:661.
22. Canonica, G. W. and Passalacqua, G. 2006. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy 81 (61 Suppl):20.
23. Passalacqua, G. and Canonica, G. W. 2006. Sublingual immunotherapy: update 2006. Curr. Opin. Allergy Clin. Immunol. 6:449.
24. Wilson, D. R., Lima, M. T. and Durham, S. R. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis. Allergy 60:4.
25. Dahl, R., Kapp, A., Colombo, G. et al. 2006. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118:434.
26. Didier, A., Malling, H. J., Worm, M. et al. 2007. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120:1338.
27. Agostinis, F., Tellarini, L., Canonica, G. W., Falagiani, P. and Passalacqua, G. 2005. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 60:133.
28. Agostinis, F., Foglia, C., Landi, M. et al. 2008. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 63:1637.
29. Grosclaude, M., Bouillot, P., Alt, R. et al. 2002. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int. Arch. Allergy Immunol. 129:248.
30. Frew, A. J. and Smith, H. E. 2001. Sublingual immunotherapy. J. Allergy Clin. Immunol. 107:441.
31. Cxuburu, N., Kweon, M. N., Song, J. H. et al. 2007. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25:8598.
32. Song, J. H., Nguyen, H. H., Cxuburu, N. et al. 2008. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105:1644.
33. Cuburu, N., Kweon, M. N., Hervouet, C. et al. 2009. Sublingual immunization with nonreplicating antigens induces antibodyforming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 183:7851.
34. Sakaguchi, G. 1982. Clostridium botulinum toxins. Pharmacol. Ther. 19:165.
35. Hatheway, C. L. 1990. Toxigenic clostridia. Clin. Microbiol. Rev. 3:66.
36. Simpson, L. L. 1986. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu. Rev. Pharmacol. Toxicol. 26:427.
37. Shapiro, R. L., Hatheway, C. and Swerdlow, D. L. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 129:221.
38. Simpson, L. L. 2004. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44:167.
39. Turton, K., Chaddock, J. A. and Acharya, K. R. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552.
40. Kiyatkin, N., Maksymowych, A. B. and Simpson, L. L. 1997. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65:4586.
41. Boles, J., West, M., Montgomery, V. et al. 2006. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47:877.
42. Morefield, G. L., Tammariello, R. F., Purcell, B. K. et al. 2008. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J. Immune. Based Ther. Vaccines 6:e5.
43. Zeng, M., Xu, Q., Elias, M., Pichichero, M. E., Simpson, L. L. and Smith, L. A. 2007. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25:7540.
44. Foynes, S., Holley, J. L., Garmory, H. S., Titball, R. W. and Fairweather, N. F. 2003. Vaccination against type F botulinum toxin using attenuated Salmonella enterica serovar Typhimurium strains expressing the BoNT/F H(C) fragment. Vaccine 21:1052.
45. Cai, S. and Singh, B. R. 2007. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infect. Disord. Drug Targets 7:47.
46. Smith, L. A. 2009. Botulism and vaccines for its prevention. Vaccine 27 (Suppl. 4):D33.
47. Byrne, M. P., Smith, T. J., Montgomery, V. A. and Smith, L. A. 1998. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66:4817.
48. Baldwin, M. R., Tepp, W. H., Przedpelski, A. et al. 2008. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76:1314.
49. Clayton, J. and Middlebrook, J. L. 2000. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 18:1855.
50. Yu, Y. Z., Zhang, S. M., Sun, Z. W., Wang, S. and Yu, W. Y. 2007. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25:8843.
51. Ginalski, K., Venclovas, C., Lesyng, B. and Fidelis, K. 2000. Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett. 482:119.
52. Swaminathan, S. and Eswaramoorthy, S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693.
53. Clapp, B., Golden, S., Maddaloni, M., Staats, H. F. and Pascual, D.W. 2010. Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol. 11:36.
54. Staats, H. F., Fielhauer, J. R., Thompson, A. L. et al. 2011. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 6:e16532.
55. Maddaloni, M., Staats, H. F., Mierzejewska, D. et al. 2006. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J. Immunol. 177:5524.
56. + regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol. 184:7144.
57. Kato, H., Fujihashi, K., Kato, R., Yuki, Y. and McGhee, J. R. 2001. Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses. J. Immunol. 166:3114.
58. Csencsits, K. L. and Pascual, D. W. 2002. Absence of L-selectin delays mucosal B cell responses in nonintestinal effector tissues. J. Immunol. 169:5649.
59. Pascual, D. W., White, M. D., Larson, T. and Walters, N. 2001. Impaired mucosal immunity in L-selectin-deficient mice orally immunized with a Salmonella vaccine vector. J. Immunol. 167:407.
60. Cleary, J. F. 1997. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin. Oncol. 24:S16-13-9.
61. åRI expression. J. Allergy Clin. Immunol. 112:141.
62. von Bubnoff, D., Fimmers, R., Bogdanow, M., Matz, H., Koch, S. and Bieber, T. 2004. Asymptomatic atopy is associated with increased indoleamine 2,3-dioxygenase activity and interleukin-10 production during seasonal allergen exposure. Clin. Exp. Allergy 34:1056.
63. Moingeon, P., Batard, T., Fadel, R., Frati, F., Sieber, J. and Van Overtvelt, L. 2006. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61:151.
64. Rusnak, J. M. and Smith, L. A. 2009. Botulinum neurotoxin vaccines: past history and recent developments. Hum. Vaccine 5:794.
65. Byrne, M. P. and Smith, L. A. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955.
66. Villar, R. G., Elliott, S. P. and Davenport, K. M. 2006. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect. Clin. North Am. 20:313.